Insights
Market commentary and guides
MPL, SHL & CSL – Finding Support
MPL, SHL & CSL are worth adding to your watch-list. We see the current price levels in these names, at or near new buying…
CSL – Outlook
CSL’s FY17 NPAT guidance implies US$1.38b net profit after tax. The company has purchased 1.4m shares during 2HFY17, of the $500 million share buy-back…
CSL and Cochlear – Valuation & Earnings Update
CSL trades 27x forward earnings. FY18 revenue to grow 5% to US$7b, EBIT +18% to US$2.2b, EPS US$3.60 & DPS US$1.70. This places CSL…
CSL: Fully Valued At Current Levels
The share price of CSL jumped almost 14% to $115.90 this week after surprising the market with a big earnings upgrade. After posting a…
Healthcare Algo Buy Signals
At this point in the market we prefer healthcare names as a sector allocation for new money. Here are the recent buy signals generated…
Healthcare – Watch For Buying Interest
Healthcare names are being sold off due to their high PE ratios and negative sentiment towards the sector, which is permeating from the US…
Algo Signal Review
The algo engine has triggered a number of ASX signals in the last 48 hours. CSL has sold-off and is worth watching, the other…
Healthcare Opportunities – add to your watch list
Within the current sell-off Resmed, Sonic Healthcare & CSL look like reasonable opportunities in a back drop of increased volatility. Here are the entry levels…
CSL FY16 Earnings Result
CSL.ASX reported FY16 revenue of $6.1b on EBITDA of $1.65b. The $500m share buyback is less than conducted in the previous 2 years but…